Viatris Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Viatris ont diminué à un taux annuel moyen de -30.1%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en à 13.5% par an. Les revenus ont augmenté de en baisse à un taux moyen de 4.2% par an.
Informations clés
-30.09%
Taux de croissance des bénéfices
-27.61%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 5.95% |
| Taux de croissance des recettes | -4.17% |
| Rendement des fonds propres | -2.88% |
| Marge nette | -2.79% |
| Dernière mise à jour des bénéfices | 30 Jun 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Sep 09
VTRS: Pipeline Reliance Will Likely Disappoint Elevated 2026 Expectations
Viatris' analyst price target framework edges higher toward $12.34. This reflects analysts' view that a slightly higher discount rate is offset by improved profit margin expectations and Street research pointing to potential revenue and EBITDA growth supported by the company's branded drug pipeline and capital allocation plans.
Mise à jour du récit • Aug 08
VTRS: Product Approvals And 2026 Outlook Will Drive Multiple Re Rating
Analysts raised their fair value estimate for Viatris from $17.94 to $18.50, reflecting updated assumptions that include a modestly higher discount rate, slightly softer revenue growth, stronger profit margin expectations, and a lower future P/E multiple following the recent $22 price target move from Barclays, which cited strong Q1 results and a supportive product approval outlook. Analyst Commentary Recent research on Viatris centers on how the stock might reflect the company’s execution on its product pipeline and revenue trajectory over the next few years.Seeking Alpha • Jul 31
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Summary Viatris is rated a sell due to persistent risks, weak financials, and a likely profit-taking event post-Q2 2026 earnings. VTRS faces significant tariff and supply chain risks from heavy reliance on Indian manufacturing, with looming 2028–2029 US tariff threats. Despite positive free cash flow and a 5.3% shareholder return, VTRS remains unprofitable and burdened by high debt and rising R&D costs. Pipeline catalysts (Meloxicam, estrogen patch) are 9–12 months out, but near-term revenue growth is minimal and margin pressures persist. Read the full article on Seeking AlphaMise à jour du récit • Jul 22
VTRS: Pipeline Approvals And 2026 Guidance Will Shape Future Re Rating Potential
Analysts have lifted the Viatris price target from $17.50 to $17.94, reflecting updated assumptions around revenue growth, profitability and future P/E multiples following what they describe as strong recent results and a supportive product approval pipeline. Analyst Commentary Recent Street research on Viatris points to a generally constructive view, with several bullish analysts lifting price targets after what they describe as strong Q1 results and a clearer product approval roadmap.
Mise à jour du récit • Jun 30
VTRS: Product Approvals And FY26 Outlook Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Viatris from $20.00 to $23.00, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple following what they describe as strong Q1 results and an improved outlook for upcoming product approvals. Analyst Commentary Bullish analysts covering Viatris are leaning into the recent Q1 report, pointing to what they see as a clearer path on both execution and valuation.Mise à jour du récit • Jun 16
VTRS: Pipeline Execution And Euro Debt Raise Will Pressure Elevated Expectations
Analysts have raised the Viatris price target by $5 to $22, citing stronger modeled revenue growth, a slightly adjusted profit margin profile, and expectations that ongoing product approvals could support a somewhat higher future P/E multiple. Analyst Commentary Recent Street research around Viatris centers on how the stock lines up on valuation against peers, how reliable the current execution looks, and what the growth path might be over the next few years.Mise à jour du récit • Jun 01
VTRS: Product Approval Execution Will Test Elevated Future Earnings Expectations
Analysts have raised their Viatris price target by $5 to $22, citing strong Q1 results and expectations that upcoming product approvals and a narrowing revenue growth gap to peers could support a higher valuation multiple over time. Analyst Commentary Street research on Viatris has recently tilted more constructive around the Q1 print, but even the more optimistic voices are still flagging execution and durability risks around the story.Mise à jour du récit • May 18
VTRS: FY26 Guidance And March Investor Event Will Shape Re Rating Potential
Analysts have raised their Viatris price target by $1.78 to $17.50, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research updates on Viatris point to a more constructive stance on the stock, with some firms lifting their valuation targets as they revisit earnings, cost savings and long term guidance assumptions.Mise à jour du récit • May 03
VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential
Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.Mise à jour du récit • Apr 19
VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential
Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.Mise à jour du récit • Apr 04
VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential
Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.Mise à jour du récit • Mar 21
VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential
Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.Mise à jour du récit • Mar 07
VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations
Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.Mise à jour du récit • Feb 20
VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk
Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.Mise à jour du récit • Feb 06
VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential
Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.Mise à jour du récit • Jan 23
VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential
Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.Mise à jour du récit • Jan 09
VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns
Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.Mise à jour du récit • Dec 25
VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance
Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.Mise à jour du récit • Dec 11
VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance
Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.Mise à jour du récit • Nov 27
VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead
Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.Mise à jour du récit • Nov 13
VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead
The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.Mise à jour du récit • Oct 30
VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth
Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.Mise à jour du récit • Oct 15
Aging Populations And Asia Markets Will Unlock Future Value
Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.Mise à jour du récit • Aug 27
Aging Populations And Asia Markets Will Unlock Future Value
The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
Nouveau récit • Apr 22
New Product Launches And Expense Savings Will Strengthen Future Operations
New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Viatris gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 26 | 14,737 | -411 | 3,368 | 1,004 |
| 31 Mar 26 | 14,563 | -296 | 3,432 | 977 |
| 31 Dec 25 | 14,300 | -3,515 | 3,469 | 953 |
| 30 Sep 25 | 14,124 | -3,691 | 3,580 | 890 |
| 30 Jun 25 | 14,116 | -3,468 | 3,640 | 844 |
| 31 Mar 25 | 14,330 | -3,790 | 3,735 | 830 |
| 31 Dec 24 | 14,739 | -634 | 3,725 | 806 |
| 30 Sep 24 | 15,049 | -883 | 3,735 | 802 |
| 30 Jun 24 | 15,239 | -646 | 3,776 | 815 |
| 31 Mar 24 | 15,361 | -56 | 3,805 | 819 |
| 31 Dec 23 | 15,427 | 55 | 3,776 | 802 |
| 30 Sep 23 | 15,466 | 1,832 | 3,720 | 782 |
| 30 Jun 23 | 15,602 | 1,854 | 3,686 | 746 |
| 31 Mar 23 | 15,800 | 1,904 | 3,580 | 700 |
| 31 Dec 22 | 16,263 | 2,079 | 3,518 | 661 |
| 30 Sep 22 | 16,728 | 804 | 3,584 | 675 |
| 30 Jun 22 | 17,187 | 761 | 3,678 | 649 |
| 31 Mar 22 | 17,648 | 168 | 4,101 | 641 |
| 31 Dec 21 | 17,886 | -1,269 | 4,245 | 668 |
| 30 Sep 21 | 17,168 | -1,921 | 4,802 | 625 |
| 30 Jun 21 | 15,604 | -2,047 | 4,382 | 603 |
| 31 Mar 21 | 13,757 | -1,728 | 3,686 | 565 |
| 31 Dec 20 | 11,946 | -670 | 2,686 | 508 |
| 30 Sep 20 | 11,514 | 266 | 2,445 | 486 |
| 30 Jun 20 | 11,504 | 271 | 2,427 | 487 |
| 31 Mar 20 | 11,624 | 63 | 2,503 | 492 |
| 31 Dec 19 | 11,501 | 17 | 2,503 | 519 |
| 30 Sep 19 | 11,387 | 48 | 2,445 | 519 |
| 30 Jun 19 | 11,288 | 34 | 2,452 | 532 |
| 31 Mar 19 | 11,245 | 240 | 2,378 | 568 |
| 31 Dec 18 | 11,434 | 353 | 2,397 | 586 |
| 30 Sep 18 | 11,594 | 546 | 2,303 | 622 |
| 30 Jun 18 | 11,719 | 457 | 2,385 | 648 |
| 31 Mar 18 | 11,873 | 717 | 2,435 | 663 |
| 31 Dec 17 | 11,908 | 696 | 2,564 | 666 |
| 30 Sep 17 | 11,937 | 869 | 2,357 | 655 |
| 30 Jun 17 | 12,007 | 661 | 2,356 | 665 |
| 31 Mar 17 | 11,605 | 533 | 2,300 | 663 |
| 31 Dec 16 | 11,077 | 480 | 2,351 | 698 |
| 30 Sep 16 | 10,300 | 257 | 2,150 | 691 |
| 30 Jun 16 | 9,938 | 806 | 2,019 | 688 |
| 31 Mar 16 | 9,749 | 805 | 1,973 | 687 |
| 31 Dec 15 | 9,429 | 848 | 1,924 | 652 |
| 30 Sep 15 | 9,021 | 842 | 1,885 | 645 |
Des revenus de qualité: VTRS n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: VTRS n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: VTRS n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 30.1% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de VTRS au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: VTRS n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( 1% ).
Rendement des fonds propres
ROE élevé: VTRS a un retour sur capitaux propres négatif ( -2.88% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/14 04:10 |
| Cours de l'action en fin de journée | 2026/09/14 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Viatris Inc. est couverte par 30 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Aaron Gal | Bernstein |